Rani Therapeutics (RANI) filed a registration statement Friday for the potential sale of up to $200 million of securities from time to time in one or more offerings.
The filing covers class A common shares, preferred stock, debt securities, and warrants.
The company said it plans to use the net proceeds for working capital and general corporate purposes.